Brought to you by 
Upsher-Smith takes 7% equity, licenses Proximagen PD molecule
11 May 2022
Executive Summary
Upsher-Smith Laboratories (women's health, dermatology, and cardiology products) has received worldwide rights to King's College London spin-off Proximagen Neuroscience PLC's PRX1 program, which is undergoing preclinical studies for Parkinson's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Upsher-Smith takes 7% equity, licenses Proximagen PD molecule
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice